Recurrent Rectal Cancer Recruiting Phase 2 Trials for Panitumumab (DB01269)

Also known as: Rectal cancer recurrent / Carcinoma rectum recurrent / Rectal carcinoma recurrent / Carcinoma of rectum recurrent

IndicationStatusPhase
DBCOND0028583 (Recurrent Rectal Cancer)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01814501Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With BevacizumabTreatment